Inflammatory cytokine signaling pathways

Inflammatory cytokine signaling pathways in immune cells are complex networks of molecular interactions that mediate the body's response to injury, infection, and stress [1.2.2, 1.2.5]. These pathways, including the JAK-STAT, NF-κB, and MAPK cascades, are triggered by the binding of pro-inflammatory cytokines—such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-1 (IL-1), and Interleukin-6 (IL-6)—to their specific cell-surface receptors [1.1.2, 1.2.3]. Upon activation, these pathways transmit signals to the nucleus to regulate the transcription of genes involved in immune cell activation, proliferation, and survival [1.2.1, 1.2.2]. Dysregulation of these signaling pathways is a hallmark of various autoimmune and chronic inflammatory diseases, where persistent activation leads to tissue damage and systemic inflammation [1.1.5, 1.2.1]. Consequently, components of these pathways are major therapeutic targets in modern medicine [1.1.1]. Therapeutic strategies include the use of monoclonal antibodies to neutralize extracellular cytokines, soluble decoy receptors to sequester ligands, and small-molecule inhibitors to block intracellular signaling enzymes like Janus kinases [1.1.1, 1.1.3]. These interventions are widely used to treat conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease [1.1.3, 1.1.5]. However, modulating these pathways carries risks, primarily related to the suppression of normal immune surveillance and increased susceptibility to infections [1.1.2, 1.1.4].

Other names

Cytokine signaling cascadesPro-inflammatory cytokine pathwaysImmune cell signaling pathways

Modulation of inflammatory responses through the neutralization of extracellular cytokines (e.g., Tumor necrosis factor-alpha, Interleukin-6), blockade of their respective receptors, or inhibition of downstream intracellular signaling enzymes such as Janus kinases (JAKs) to prevent pro-inflammatory gene transcription [1.1.1, 1.1.3].